In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

In a real-world study, only 35% of patients completed the full guideline-recommended 4-6 cycles of chemotherapy as first-line treatment for metastatic bladder cancer. Real-world data show ...

The median duration of response was 6 months. Treatment with pembrolizumab and fulvestrant provided disease control in half of patients with estrogen receptor (ER)-positive, HER2-negative ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window My main ...